Drug Trial Radar · NCT02363998
Open-Label, Safety Study of Lofexidine
Last checked: Nov 20, 2026Latest source record: Mar 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
286
Actual
Start
Feb 2015
Primary completion
Sep 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- USWM, LLC (dba US WorldMeds)Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Feb 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 3 open-label treatment study is to evaluate the safety and effectiveness of lofexidine at a clinically relevant dose to alleviate symptoms of acute withdrawal from any opioid, including methadone and buprenorphine. This study will take place in a variety of clinical scenarios, both in-clinic and outpatient settings.
Conditions
- Opioid Withdrawal
Interventions
LofexidineDrug
All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Days 1-14
- Overall Occurrence of Serious Treatment Emergent Adverse Events (Serious TEAEs)Time frame: Days 1-14
- Overall Treatment Emergent Adverse Events (TEAEs) by SeverityTime frame: Days 1-14
- Occurrence of Per Protocol Adverse Events of Special Interest (AESI)Time frame: Day 1 to Day 14
- Occurrence of Adverse Events (AEs) Not Related to Opioid WithdrawalTime frame: Day 1 to Day 14
- Mean Observed and Change From Screening in Seated Systolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
- Mean Observed and Change From Screening in Standing Systolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
- Mean Observed and Change From Screening in Seated Diastolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
- Mean Observed and Change From Screening in Standing Diastolic Blood Pressure (mmHg): Vital SignTime frame: Day 1 to Day 14
- Mean Observed and Change From Screening in Seated Pulse (Bpm): Vital SignsTime frame: Day 1 to Day 14
- Mean Observed and Change From Screening in Standing Pulse (Bpm): Vital SignsTime frame: Day 1 to Day 14
- Columbia Suicide Severity Rating Scale Questionnaire (C-SSRS): Suicidal Ideation and Behavior NumbersTime frame: Day 1 to Day 14
- Clinical Laboratory Test Change From Baseline: HematologyTime frame: Day 1 to Day 14
- Clinical Laboratory Test Change From Baseline: ChemistryTime frame: Day 1 to Day 14
- Clinical Laboratory Test Change From Baseline: UrinalysisTime frame: Day 1 to Day 7
- Safety Electrocardiograms (ECG) Evaluation Shift From Baseline to Post Dose and End of StudyTime frame: Day 1 and Day 14
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Little Rock, Arkansas
Site not named
Springdale, Arkansas
Site not named
San Diego, California
Site not named
Fort Lauderdale, Florida
Site not named
Hollywood, Florida
Site not named
Orlando, Florida
Site not named
Atlanta, Georgia
Site not named
Winfield, Illinois
Site not named
Lake Charles, Louisiana
Site not named
Rockville, Maryland
Site not named
Flowood, Mississippi
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Dayton, Ohio
Site not named
Portland, Oregon
Site not named
Pittsburgh, Pennsylvania
Site not named
North Charleston, South Carolina
Site not named
Orem, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.